Biological Products, (No Diagnostic Substances) · CAMBRIDGE, MA, United States
$29.24
+9.06% (+$2.43)2026-06-18
Smart-Money SignalAccumulation · 59/100— Insiders are net buyers over 90 days ($55.5M, 20 buys vs 10 sales)
Price Performance
Historical data including institutional events
Company Profile
B
Benny Sorensen
CEO & Executive Director
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.
It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
